Pharma Mar SA (Pharma Mar) discovers, develops, manufactures, and commercialises marine-derived drugs for the treatment of cancer.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company is actively engaged in research and development initiatives focused on oncology and RNA interference. It conducts clinical trials in various stages, including Phase I, II, and III trials for compounds like lurbinectedin, ecubectedin, PM54, and PM534 in solid tumors. The company is exploring new indications for existing drugs, such as Zepzelca, and is involved in the development of RNAi-based treatments for ophthalmology. Pharma Mar has increased its R&D expenditure to support these initiatives, with a focus on innovation and strategic alliances to advance its compounds through research phases and subsequent marketing. The R&D activities of Pharma SA are managed through a horizontal working structure across various departments, project-specific teams, and reporting systems. This structure is designed to maximise the effective and efficient use of resources in researching and developing new pharmaceutical products. The company also has a rigorous patent policy to protect inventions obtained through its R&D activities. The company operates in a 4,200 m² R&D laboratory. It actively seeks protection for new formulations, production processes, medical applications, and new methods of drug administration. The company is working on multiple pipeline products, including lurbinectedin, ecubectedin, PM54, PM534, and SYL1801. It has licensing agreements with international partners for marketing its compounds outside Europe and is involved in collaborative projects with public institutions and private companies. In FY2024, Pharma Mar spent EUR 103.502 million on its R&D, which as a percentage of revenue, stood at 56.7% and increased 4.2%.